https://mindmedicinelaw.com/briefing/ketamine-vs-psilocybin-depression-outcomes-and-durability-compared-20261017-51315The Psychedelic Journalen2026-10-18T15:06:21.996676+00:00Ketamine vs Psilocybin: Depression Outcomes and Durability Comparedketamine, psilocybin, treatment-resistant depression, clinical trial comparison, remission durability, cost-effectiveness, psychedelic therapy, payer coverage, trial design, mental health policyhttps://mindmedicinelaw.com/briefing/psychedelic-trial-participants-challenge-clinical-protocols-20261017-51042The Psychedelic Journalen2026-10-17T15:06:44.591755+00:00Psychedelic Trial Participants Challenge Clinical Protocolspsychedelic clinical trials, participant experience, integration support, outcome measures, FDA guidance, patient-centered research, MDMA trials, trial design limitations, ethics in researchhttps://mindmedicinelaw.com/briefing/public-doubt-and-antidepressant-efficacy-implications-for-psychedelic-policy-20261016-51269The Psychedelic Journalen2026-10-18T15:07:12.202550+00:00Public Doubt and Antidepressant Efficacy: Implications for Psychedelic Policyantidepressant skepticism, psychedelic policy, manufactured doubt, critical psychiatry, public trust in science, regulatory implications, serotonin hypothesis, psychiatric treatment debate, science communication, philosophy of sciencehttps://mindmedicinelaw.com/briefing/iv-vs-subcutaneous-esketamine-for-trd-real-world-outcomes-in-brazil-20261016-51316The Psychedelic Journalen2026-10-18T15:06:33.950677+00:00IV vs. Subcutaneous Esketamine for TRD: Real-World Outcomes in Brazilesketamine, treatment-resistant depression, intravenous administration, subcutaneous administration, real-world evidence, brazil, clinical outcomes, adverse events, psychiatric protocolshttps://mindmedicinelaw.com/briefing/oregon-s-psilocybin-centers-face-scrutiny-over-therapy-standards-20261016-51212The Psychedelic Journalen2026-10-17T22:04:35.692573+00:00Oregon’s Psilocybin Centers Face Scrutiny Over Therapy Standardsoregon psilocybin centers, psychedelic therapy standards, measure 109, clinical integration, regulatory oversight, undercover investigation, public health risk, facilitator training, policy implications, psychedelic-assisted carehttps://mindmedicinelaw.com/briefing/esketamine-and-wnt4-signaling-preclinical-insights-from-rat-pain-depression-mode-20261016-50978The Psychedelic Journalen2026-10-17T15:07:00.876965+00:00Esketamine and Wnt4 Signaling: Preclinical Insights from Rat Pain-Depression Modelsesketamine, pain-depression dyad, wnt4 signaling, anterior cingulate cortex, preclinical research, transcriptomics, molecular mechanisms, clinical translation, psychedelic neurosciencehttps://mindmedicinelaw.com/briefing/ketamine-s-synaptic-and-monoaminergic-effects-in-human-ipsc-neurons-20261016-50979The Psychedelic Journalen2026-10-17T15:05:29.239434+00:00Ketamine’s Synaptic and Monoaminergic Effects in Human iPSC Neuronsketamine, iPSC-derived neurons, synaptic remodeling, monoaminergic signaling, antidepressant mechanisms, precision psychiatry, translational neuroscience, akt pathway, drug development, treatment-resistant depressionhttps://mindmedicinelaw.com/briefing/ibogaine-5-meo-dmt-adverse-outcomes-us-survey-insights-20261016-50964The Psychedelic Journalen2026-10-17T15:05:13.712439+00:00Ibogaine, 5-MeO-DMT Adverse Outcomes: US Survey Insightsibogaine adverse effects, 5-meo-dmt safety, psychedelic survey, cardiac risk psychedelics, clinical trial design, psychedelic regulation, self-reported outcomes, public health, psychedelic therapy riskshttps://mindmedicinelaw.com/briefing/controlled-vocabulary-gaps-in-depression-biomarker-indexing-implications-for-psy-20261015-50981The Psychedelic Journalen2026-10-17T15:07:16.536875+00:00Controlled Vocabulary Gaps in Depression Biomarker Indexing: Implications for Psychedelic Trialsmesh indexing, biomarker sampling site, depression research, psychedelic clinical trials, systematic review bias, inflammatory endotype, regulatory evidence, bibliographic infrastructure, meta-research, controlled vocabularyhttps://mindmedicinelaw.com/briefing/ketamine-induced-cystitis-clinical-risks-and-policy-implications-20261015-50984The Psychedelic Journalen2026-10-17T15:06:12.117387+00:00Ketamine-Induced Cystitis: Clinical Risks and Policy Implicationsketamine-induced cystitis, bladder toxicity, recreational ketamine use, medical ketamine risks, urothelial inflammation, clinical management, policy implications, addiction medicine, urological complications, evidence gapshttps://mindmedicinelaw.com/briefing/ketamine-assisted-psychotherapy-alters-dna-methylation-in-mdd-patients-20261015-50950The Psychedelic Journalen2026-10-17T15:05:57.459781+00:00Ketamine-Assisted Psychotherapy Alters DNA Methylation in MDD Patientsketamine-assisted psychotherapy, dna methylation, major depressive disorder, notch signaling pathway, biomarker development, psychedelic research, clinical trials, molecular mechanisms, regulatory sciencehttps://mindmedicinelaw.com/briefing/emotional-bias-markers-and-esketamine-response-in-trd-clinical-implications-20261015-50982The Psychedelic Journalen2026-10-17T15:05:41.881532+00:00Emotional Bias Markers and Esketamine Response in TRD: Clinical Implicationsesketamine, treatment-resistant depression, emotional bias, response criterion, clinical response markers, psychedelic therapy, measurement-based care, precision psychiatry, nmda antagonist, depression biomarkershttps://mindmedicinelaw.com/briefing/ketamine-and-esketamine-for-severe-depression-efficacy-and-safety-in-acute-suici-20261014-51330The Psychedelic Journalen2026-10-18T15:06:46.309350+00:00Ketamine and Esketamine for Severe Depression: Efficacy and Safety in Acute Suicidality (Brazil, 2026 Review)ketamine, esketamine, severe depression, suicidality, clinical safety, rapid-acting antidepressants, treatment-resistant depression, adverse events, policy implications, Brazilhttps://mindmedicinelaw.com/briefing/ibogaine-review-for-substance-use-disorders-2026-pubmed-update-20261014-51022The Psychedelic Journalen2026-10-17T15:07:31.875042+00:00Ibogaine Review for Substance Use Disorders: 2026 PubMed Updateibogaine, substance use disorders, psychedelic research, clinical trials, pharmacogenetics, regulatory policy, public health, safety risks, addiction treatment, neurobiologyhttps://mindmedicinelaw.com/briefing/group-psilocybin-retreats-and-social-connection-case-insights-20261014-50975The Psychedelic Journalen2026-10-17T15:06:28.337306+00:00Group Psilocybin Retreats and Social Connection: Case Insightspsilocybin, group therapy, psychedelic retreats, social connectedness, clinical trials, regulatory policy, community models, mental health, safety protocols, observational studieshttps://mindmedicinelaw.com/briefing/antidepressants-cognition-and-psychedelics-precision-medicine-for-mdd-20261013-50976The Psychedelic Journalen2026-10-17T22:04:49.478024+00:00Antidepressants, Cognition, and Psychedelics: Precision Medicine for MDDantidepressants, cognitive function, major depressive disorder, psychedelic compounds, ketamine, clinical trial design, precision medicine, vortioxetine, regulatory guidancehttps://mindmedicinelaw.com/briefing/ethical-and-practical-dimensions-of-patient-safety-in-es-ketamine-therapy-german-20261008-51298The Psychedelic Journalen2026-10-18T15:07:00.074642+00:00Ethical and Practical Dimensions of Patient Safety in (Es)ketamine Therapy: German Clinical Insightsesketamine therapy, patient vulnerability, ethical care, clinical safety, psychedelic therapy, german psychiatric settings, therapeutic presence, post-acute support, informed consent, standards of care